SCHEMBL5497210

SCHEMBL5497210

Cc1ccc(C(N)=O)cc1-c1ccc2nc(NCCCN3CCOCC3)ncc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.72
KDR P35968 10/20 0.72
LCK P06239 9/20 0.72
MAPK9 P45984 2/20 0.72
MAPK10 P53779 2/20 0.72
KIT P10721 2/20 0.72
RIPK1 Q13546 1/20 0.70
RIPK3 Q9Y572 1/20 0.70
JAK3 P52333 4/20 0.69
SRC P12931 2/20 0.63
TYK2 P29597 1/20 0.63
SYK P43405 1/20 0.63
MAPK8 P45983 1/20 0.63
BTK Q06187 1/20 0.63
AR P10275 1/20 0.59
KDM4E B2RXH2 2/20 0.47
FGFR4 P22455 2/20 0.46
CSNK2A1 P68400 1/20 0.45
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5496169 0.89 MAPK14 (0.91) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5501508 0.86 MAPK14 (0.83) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5494152 0.85 RIPK1 (0.76) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL14724709 0.84 MAPK14 (0.78) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5494563 0.84 RIPK1 (0.63) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5505067 0.84 MAPK14 (1.00) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5489786 0.83 LCK (0.58) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5494923 0.82 MAPK14 (0.75) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5495638 0.82 MAPK14 (0.78) MAPK14KDRLCKMAPK9MAPK10
SCHEMBL5498815 0.82 MAPK14 (0.94) MAPK14KDRLCKMAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 MAPK14 301/4885KDR 1044/4885LCK 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.